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Progenitor-like cells derived from mouse
kidney protect against renal fibrosis in a
remnant kidney model via decreased
endothelial mesenchymal transition
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Abstract
Introduction: Pathophysiological changes associated with chronic kidney disease impair angiogenic processes and
increase renal fibrosis. Progenitor-like cells derived from adult kidney have been previously used to promote
regeneration in acute kidney injury, even though it remained unclear whether the cells could be beneficial in
chronic kidney disease (CKD).
Methods: In this study, we established a CKD model by five-sixths nephrectomy and mouse kidney progenitor-like
cells (MKPCs) were intravenously administered weekly for 5 weeks after establishing CKD. We examined the impact
of MKPCs on the progression of renal fibrosis and the potential of MKPCs to preserve the angiogenic process and
prevent endothelial mesenchymal transition in vivo and in vitro.
Results: Our results demonstrate that the MKPCs delayed interstitial fibrosis and the progression of glomerular
sclerosis and ameliorated the decline of kidney function. At 17 weeks, the treated mice exhibited lower blood
pressures, higher hematocrit levels, and larger kidney sizes than the control mice. In addition, the MKPC treatment
prolonged the survival of the mice with chronic kidney injuries. We observed a decreased recruitment of
macrophages and myofibroblasts in the interstitium and the increased tubular proliferation. Notably, MKPC both
decreased the level of vascular rarefaction and prevented endothelial mesenchymal transition (EndoMT) in the
remnant kidneys. Moreover, the conditioned medium from the MKPCs ameliorated endothelial cell death under
hypoxic culture conditions and prevented TGF-β-induced EndoMT through downregulation of phosphorylated
Smad 3 in vitro.
Conclusions: MKPCs may be a beneficial treatment for kidney diseases characterized by progressive renal fibrosis.
The enhanced preservation of angiogenic processes following MKPC injections may be associated with decreased
fibrosis in the remnant kidney. These findings provide further understanding of the mechanisms involved in these
processes and will help develop new cell-based therapeutic strategies for regenerative medicine in renal fibrosis.
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Introduction
Chronic kidney disease (CKD) is a global public health
concern, and its burden continues to increase around
the world, as demonstrated by increases in attributable
deaths and the incidence of end-stage renal disease
(ESRD) [1]. Regardless of the underlying causes, CKD
features progressive loss of glomerular function associ-
ated with the presence of tubulointerstitial lesions and
peritubular capillary rarefaction. At present, the thera-
peutic strategy for slowing the renal progression of CKD
involves controlling blood pressure, using angiotensin-
converting enzyme inhibitors or angiotensin II receptor
blockers, and restricting protein [2]. The effects of these
modalities remain insufficient, however, and in most
cases CKD leads to ESRD.
Stem cell-based therapy is a new strategy for treating
chronic kidney injury and may be more effective than
single-agent drug therapy because stem cells exhibit
highly versatile responses to their environments. Stem
cells may secrete cytokines within injured kidneys and
participate in endothelial cell proliferation or angiogen-
esis to facilitate renal regeneration [3, 4]. Increasing evi-
dence has suggested there is therapeutic potential in
using mesenchymal stem cells derived from bone mar-
row to treat chronic kidney injury [5–10]. The important
challenge of clinical translation is the risk for long-term
maldifferentiation. This leads to the necessity of applying
progenitor or stem cells that are derived from kidney to
treat chronic kidney injury.
Mouse kidney progenitor-like cells (MKPCs) isolated
from Myh9-targeted mutant mice have exhibited pluri-
potent activity, both in vitro and in vivo [11]. As we have
demonstrated previously, these cells are renoprotective
when injected directly into the kidney of a mouse with
acute kidney injury. We determined whether weekly injec-
tions of MKPCs slowed the progression of CKD among
mice following five-sixths nephrectomy. In this study, we
provide evidence that the antifibrotic activity of MKPCs is
mediated by a novel endocrine mechanism of action, dem-
onstrating that conditioned medium derived from MKPCs
inhibits transforming growth factor beta (TGF-β)-in-
duced endothelial–mesenchymal transition (EndoMT)
in vitro. We further demonstrate the relevance of these
findings in vivo, showing that intravenous administration
of MKPCs could protect five-sixths nephrectomized




The MKPCs were isolated from the kidneys of 2-month-
old Myh9-targeted mutant mice and cultured as described
previously [11]. Briefly, kidneys were perfused in vivo with
saline to flush out the blood from the kidney, dissected,
minced, and digested with collagenase 0.3 % and trypsin
0.3 % at 37 °C for 30 minutes in a shaking water bath.
After passing through 100 μm mesh to remove undigested
chunk, glomeruli, and large renal tubules, the filtered frac-
tion was homogenized in a Dounce homogenizer for 10
strokes and then 40 μm mesh was used to remove smaller
renal tubules and cell aggregates. The filtered fraction
containing mainly single cells was washed in a medium
that consisted of DMEM-LG (Dulbecco's Modified Eagle
Medium low glucose), 100 U/ml penicillin, 100 μg/ml
streptomycin, and 100 μg/ml gentamicin with 10 %
CCS (comic calf serum). Similar cell preparations from
C57BL/6J mice were used to determine the level of auto-
fluorescence. The cells prepared from Myh9-targeted mu-
tant mouse that express green fluorescence 10-fold higher
than those from C57BL/6J mouse were sorted by
fluorescence-activated cell sorting (FACS) using FACSAria
Cell Sorter (BD Biosciences, New Jersey, USA) equipped
to sort green fluorescent protein (GFP). After sorting,
GFP-positive cells were plated and cultured on plastic
plates in DMEM-LG with 100 U/ml penicillin, 100 μg/ml
streptomycin, and 10 % CCS (Hyclone, Pittsburgh, USA)
at 37 °C in the presence of 5 % CO2.
Mouse care
Female C57BL/6 mice 8–10 weeks old of approximately
similar weights (20–25 g) were housed under pathogen-free
conditions. All animal experiments were performed after
attaining approval from the Institutional Animal Care and
Use Committee of Kaohsiung Veterans General Hospital
and according to the Guidelines for the Care and Use of
Laboratory Animals of the National Research Council.
CKD mouse model and MKPC treatment
We developed a mouse CKD model using the following
modified protocol. Surgery was performed after anesthe-
tizing the mice with a mixture of ketamine (100 mg/ml)
and xylazine (25 mg/ml). A 1:10 dilution of the stock so-
lution in saline was intraperitoneally administered at
0.02 ml/g body weight. Lateral dorsal longitudinal inci-
sions were made to expose the right-side kidney. The
upper and lower poles of the right kidney were ampu-
tated using electrocoagulation. Left nephrectomy was
performed 1 week later. The left kidney was removed
and the vascular pedicle was ligated at the hilum using
4–0 silk. The time of left nephrectomy marked the onset
of chronic kidney injury. For the MKPC treatment, in
vitro expanded MKPCs (2.5 × 105 cells in 150 μl of 0.9 %
saline) were intravenously administered to the CKD
mice through the tail vein each week from weeks 5 to
10. The control mice underwent an identical five-sixths
nephrectomy protocol and intravenously received
0.9 % saline at the same volume used in the cell therapy
(Additional file 1: Figure S1).
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Blood pressure was measured in anesthetized mice
using an automated tail-cuff manometer system (MK-
2000ST; Muromachi Kikai, Tokyo, Japan). Blood pressure
was measured at least three times and averaged. Blood
was sampled via the retro-orbital sinus of the mice. After
sacrificing the mice, one hemisection of the kidney was
obtained and processed for formalin fixation followed by
paraffin embedding or section freezing. The sections were
stained with hematoxylin and eosin, periodic acid–Schiff
(PAS), Masson’s trichrome, and silver, and then histologi-
cally examined for morphological changes. Another hemi-
section of kidney was also frozen using liquid nitrogen
and maintained frozen for further use.
Renal function was assessed by measuring blood urea
nitrogen (BUN), serum creatinine, urine protein, and
urine creatinine with a quantitative colorimetric assay
kit (Sigma, St. Louis, MO, USA). Serum cystatin C was
measured with an enzyme-linked immunosorbent assay
(ELISA) kit (Mouse Cystatin C DuoSet ELISA; R&D,
Minneapolis, MN, USA). The data are expressed as
mean ± standard deviation (SD). The groups were com-
pared based on the results of nonparametric testing. P
<0.05 indicated the presence of a significant difference.
Immunohistochemistry and immunofluorescence
The fixed kidney sections were deparaffinized in xylene
and rehydrated through a graded ethanol series to water.
After blocking the samples with 10 % normal horse serum
in phosphate-buffered saline (PBS), the slides were stained
with primary antibodies overnight at 4 °C, and then
biotinylated with secondary antibodies for 30 minutes and
diaminobenzidine reagent (Vector Laboratories, Burlin-
game, CA, USA) for 5 minutes. The primary antibodies
used were mouse anti-alpha-smooth muscle actin (anti-
αSMA; Dako Cytomation), mouse monoclonal anti-F4/80
(AbD Serotec, Raleigh, NC, USA), mouse monoclonal
anti-Ki67 (Upstate, New York, USA), mouse monoclonal
anti-GFP (Santa Cruz Biotechnology, Inc.), and anti-CD31
(Abcam, Cambridge, UK ). N-Histofine® Simple Stain™
Mouse MAX PO (Nichireibiosciences, Tokyo, Japan) was
used as secondary antibody. In immunofluorescence,
mouse anti-human smooth muscle actin (Dako Cytoma-
tion, Carpinteria, CA , USA) and rabbit anti-mouse CD31
(Santa Cruz, Texas, USA) were used as primary anti-
bodies. Goat anti-mouse IgG (Molecular Probes) and goat
anti-rabbit IgG (Molecular Probes, Oregon, USA) were
used as secondary antibodies.
Histological sections (4 μm thick) were stained with Mas-
son’s trichrome, hematoxylin and eosin, or silver, and sub-
sequently examined using light microscopy to determine
the levels of glomerular injury, interstitial fibrosis, and
tubular atrophy. The extent of glomerulosclerosis was eval-
uated at 14 and 17 weeks after the five-sixths nephrectomy.
A glomerulosclerosis index was derived for each animal by
examining at least 20 glomeruli at × 400 magnification. The
severity of glomerulosclerosis was expressed on an arbitrary
scale from 0 to 2: grade 0 = normal glomeruli; grade
1 =mild/moderate segmental glomerular hyalinosis/scler-
osis involving <50 % of the glomerular tuft; and grade
2 = diffuse glomerular hyalinosis/sclerosis involving ≥50 %
of the tuft. The resulting index for each animal was
expressed as the mean of all scores obtained.
The fractional area of the interstitial fibrosis in the renal
cortex was determined using morphometry, involving a
video camera connected to an image analyzer (Image-Pro
Plus; Olympus,Tokyo, Japan). In each renal cortex, 20 grid
fields (each 0.145 mm2 in area) were evaluated. The inter-
stitial areas were first manually circled on a video screen
and then determined using computerized morphometry.
Tubular atrophy was defined based on thick, irregular
tubular basement membranes exhibiting a simplified
epithelium. The extent of tubular atrophy was expressed
based on the total area of atrophic tubules divided by the
entire interstitial area. In each animal cortex, 20 grid fields
were evaluated. The resulting index for each animal was
expressed as the mean of all scores obtained.
For quantification of α-SMA, F4/80 or Ki67 positively
stained cells, cells were counted from 10 random cortical
fields (×200 magnification) in each section, and the num-
bers were averaged for each section. To assess the capil-
lary density, the mean area fraction of CD31-positive
peritubular capillaries in each visual field at × 200 magnifi-
cation in the light microscope were counted. Images were
analyzed by Image Pro software (Media Cybernetics,
Rockville, MD, USA) from 10 random fields in each sec-
tion, and the numbers averaged for each section.
Tracking GFP-positive cells
The MKPCs were injected into the tail veins of mice
5 weeks after they underwent five-sixths nephrectomy. The
animals were sacrificed 4 hours, 16 hours, 1 day, 2 days,
7 days, or 28 days after the MKPC injection. The kidneys
were perfused with saline to flush out blood, dissected,
minced, and digested with 0.3 % collagenase and 0.3 % tryp-
sin at 37 °C for 30 minutes in a shaking water bath. After
being passed through 40 μm mesh to remove the cell
aggregates, the cells were recovered in a medium that
consisted of DMEM-LG (Gibco, Life Technologies, NY,
USA ), 100 U/ml penicillin (Gibco), 100 μg/ml strepto-
mycin (Gibco), and 100 μg/ml gentamicin (Gibco) with
10 % CCS (Hyclone). The cells subsequently underwent
flow cytometry (FACSCalibur; BD Biosciences). Similar cell
preparations from C57BL/6J mice were used to determine
the level of autofluorescence, and cells from Myh9-targeted
mutant mice were used as positive controls.
We quantified GFP-containing cells in the lungs after
intravenous injection of 2.5 × 105 MKPCs in week 5 into
mice subjected to five-sixths nephrectomy, and the lungs
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were harvested, lysed with collagenase, and centrifuged to
obtain cell suspension. Quantification of GFP-containing cells
was made by flow cytometry. Lung obtained from a Myh9-
targeted mutant mouse was used as a positive control while
lung from a C57BL/6 mouse was used as a negative control.
Preparing the conditioned medium
The MKPCs were plated at 5000 cells/cm2 and incubated in
the aforementioned culture medium for 1 day. The attached
cells were washed three times with PBS, and the medium
was replaced with DMEM to generate a serum-free and
glucose-free medium. The cells were then incubated for
2 days and the conditioned medium was harvested.
Endothelial cell culture
Mouse pancreatic microvascular endothelial cells (MMECs)
were grown in a 5 % CO2 atmosphere at 37 °C in DMEM
containing 10 % fetal bovine serum. Recombinant human
TGF-β (R&D Systems) with or without conditioned
medium was added to the cell cultures for 14 days at con-
centrations of 1 and 5 ng/ml. The treated cells subse-
quently underwent western blotting.
Culture under hypoxic conditions
The MMECs were expanded under standard normoxic
conditions for cell cultures at 37 °C in a humidified in-
cubator containing 21 % O2, 5 % CO2, and 74 % N2. To
examine hypoxia-induced MMEC cell death, the cells
were plated in a 6 cm dish and incubated for 2 days
under standard conditions. Incubation was continued
under normoxic or hypoxic conditions with or without
conditioned medium for 24 and 28 hours. With regards
to the hypoxic conditions, the cultures were placed in an
atmosphere-controlled CO2 incubator containing a gas
mixture composed of 94 % N2, 5 % CO2, and 1 % O2.
The nitrogen was fed from a tank of liquid N2. Following
the ischemic incubation, the cell cultures were removed
from the hypoxic chamber, rinsed with PBS, observed
under a microscope, and collected for immunocytochem-
istry or flow cytometry. The experiments were repeated in
triplicate.
Immunocytochemistry
The cells were fixed with 4 % paraformaldehyde solution
and quenched with 50 mmol/l ammonium chloride.
After permeabilization with 0.1 % (v/v) Triton X-100
and blocking with 1 % horse serum, the cells were incu-
bated with primary antibodies for 1 hour, and then with
fluorophore-conjugated secondary antibodies for 40–60
minutes at room temperature. The employed antibodies
were anti-CD31 and anti-αSMA. Secondary antibodies
were also employed and 4′,6-diamidino-2-phenylindole
(DAPI) staining was used to facilitate the detection of
the nuclei.
Flow cytometry
For flow cytometry, the collected cells were suspended
in PBS. A minimum of 150,000 cells were collected for
all analyses. Gating was constructed based on the nega-
tive controls, and compensation controls were included
in all analyses. Population percentages and numbers
were generated for the gated populations in each experi-
ment using WinMDI software version 2.8 (The Scripps
Research Institute, La Jolla, CA, USA). For the apoptosis
assay, we employed an annexin V binding assay. Briefly,
cells in 6 cm culture plates were collected and double-
stained with annexin V–fluorescein isothiocyanate
(FITC) and propidium iodide (PI) using an annexin
V–FITC Apoptosis Detection Kit (Roche, New York,
USA). The stained cells were processed by conducting
flow cytometry analysis using a FACSCalibur cytometer
(BD Biosciences). The fraction of cells that was annexin
V-positive and PI-positive was considered apoptotic, and
the fraction of cells that was annexin V-negative and
PI-positive was considered necrotic. The sum of both
fractions was considered the cell death ratio.
Western blot analysis
Cell culture samples were sonicated and resuspended in
0.4 ml RIPA lysis buffer. The protein concentrations were
estimated using a detergent-compatible protein assay kit
(Bio-Rad, Hercules, CA, USA). Samples containing 18 μg
total protein were blotted with anti-CD31 and anti-αSMA.
The blots were then incubated with peroxidase-conjugated
goat anti-rabbit immunoglobulin G (IgG) or goat anti-mouse
IgG (Santa Cruz), and the bound antibody was detected
using ECL (Visual Protein Biotechnology Taipei, Taiwan) and
captured using the Epson Perfusion V350 Photo system
(Epson, Long Beach, CA, USA). Densitometry analysis was
performed using a UN-SCAN-IT gel 6.1 analyzer (Silk Scien-
tific Corporation, Orem, UA, USA). To control the loading,
the blots were incubated with actin antibody (Santa Cruz).
Results
MKPCs ameliorate renal dysfunction in the five-sixths
nephrectomy model
MKPCs were isolated and characterized before being
administered to the animals by the methods used in our
previous study [11]. To determine whether MKPCs
influenced renal function, we measured the BUN levels
in mice that underwent the five-sixths nephrectomy to
induce CKD and subsequently received injections of
either MKPCs or saline. The mice developed CKD, exhi-
biting increased interstitial fibrosis, tubular atrophy, and
glomerular sclerosis (Fig. 1a). The remnant kidneys in
the mice receiving saline yielded significantly increased
serum BUN and creatinine levels from weeks 11 through
21. The injection of MKPCs protected renal function,
and was demonstrated by the significantly lower BUN
Chen et al. Stem Cell Research & Therapy  (2015) 6:239 Page 4 of 12
and creatinine values at weeks 17 and 21 (Fig. 1b) in the
MKPC-treated mice compared with the BUN and cre-
atinine values in the saline-treated mice. To exclude the
possibility that saline alone already has an ameliorating
effect on renal function, we have measured renal func-
tion in mice that underwent five-sixths nephrectomy
without receiving any injection. As compared with mice
receiving weekly saline intravenous injection from weeks 5
to 10, mice without any injection exhibited similar renal
function (Additional file 2: Figure S2). Moreover, mice of
the MKPC group received MKPCs dissolved in saline, the
same amount as those in mice of the saline group. This
eliminates the confounding effect of saline injection in our
study. Blood pressure in the normal mice was 65.3 ±
14.7 mmHg. The mice treated with MKPCs displayed not
only decreased mean blood pressure levels, but also in-
creased hematocrit levels and larger kidney sizes (Fig. 1c).
MKPCs prolong the survival of mice with chronic kidney
injuries
We further tested whether the MKPC treatment affected
survival, which is the critical outcome following chronic
kidney injury. Figure 1d shows the survival curves of the
mice with chronic kidney injuries treated with saline and
those of the mice treated with MKPCs (n = 50). The
mice injected with the MKPCs survived significantly lon-
ger than the saline-treated mice (P = 0.01). At week 11,
only two of the mice (4 %) who were injected with MKPCs
had died, whereas 14 % of the mice in the saline group
had died. At week 21, the percentage of surviving MKPC-
treated mice remained at 94 %, whereas only 74 % of the
saline-treated mice were still alive. These results indicate
that the MKPCs both rescue renal injuries and prolong
survival in mice after five-sixths nephrectomy.
MKPCs preserve renal morphology in the five-sixths neph-
rectomy model
Improved renal function following the MKPC treatment
was also associated with enhanced preservation of the
renal structure (Fig. 2). The kidneys treated with only sa-
line had increased levels of glomerular sclerosis (Fig. 2b,
c), extensive interstitial fibrosis (Fig. 2h, i), and marked
tubular atrophy (Fig. 2m). By contrast, the kidneys
treated with MKPCs exhibited markedly reduced histo-
logical features of renal fibrosis. The glomerular sclerosis
index was also significantly lower among the MKPC
group (Fig. 2f ). In addition to the lesions observed in the
glomeruli, the fractional interstitial area (Fig. 2l) and
atrophic tubule area (Fig. 2o) also decreased in mice
injected with the MKPCs by week 17.
Fig. 1 MKPC injections improve renal function and prolong survival. a Wild-type mice present normal renal morphology without any abnormalities
(left) compared with mice receiving five-sixths nephrectomy that exhibit chronic kidney injury (right), as shown in representative Masson’s trichrome
staining pictures of kidney sections from mice 17 weeks after five-sixths nephrectomy. Black arrows point to interstitial fibrosis, stars indicate tubular
atrophy, and arrowheads represent glomerular sclerosis. Scale bar: 100 μm. b Serial BUN and serum creatinine levels measured in five-sixths
nephrectomized mice (n = 6 in each group) that received saline (triangles) or MKPC (diamonds). MKPC administration weekly from weeks 5 to
10 after establishment of chronic kidney injury significantly improves renal function at 17 and 21 weeks, whereas saline-treated mice show no
such effect. *P <0.02, MKPC-treated vs. saline-treated mice. c Five-sixths nephrectomized mice treated with MKPCs feature lower blood pressures,
higher hematocrit, and larger kidney size at 17 weeks compared with mice treated with saline (n = 6 in each group). d MKPC treatment prolongs
survival in mice with chronic kidney injury. Kaplan–Meier survival in the MKPC group vs. the saline group. The survival differences between these two
groups were tested with the log-rank test that shows a statistical significant difference (P = 0.01). Mice given MKPCs survived significantly longer than
PBS-treated mice. b, c Data presented as mean ± SD. Hct hematocrit, MBP mean blood pressure, MKPC mouse kidney progenitor-like cells
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In vivo tracking of MKPCs
To quantify the GFP-positive cells present in the kidneys
after the five-sixths nephrectomy, the mice were injected
once with 2.5 × 105 MKPCs 5 weeks after establishing
chronic kidney injury. The cells containing GFP were
quantified using flow cytometry and the results are pre-
sented in Fig. 3a. The presence of GFP-positive cells in
the remnant kidneys was transient, increasing at 4 hours,
peaking at 2 days, and declining at 7 days. By 28 days
after a single injection of MKPCs, scant GFP-positive
cells were detected in the remnant kidneys. To evaluate
whether the MKPCs could be incorporated into parts of
the remnant kidneys, we traced the MKPCs by staining
the GFP in mice 14 and 17 weeks after the five-sixths
nephrectomy. Only a limited area of the medulla exhib-
ited evidence that the injected MKPCs were being incor-
porated into renal tubules (Fig. 3d) or were scattered in
the interstitium (Fig. 3e). It is widely accepted that injec-
tion of cells via the tail vein leads to accumulation of
cells in the lungs. To eliminate the long-term effect of
MKPCs in the lungs, we quantified GFP-positive cells in
the lungs after intravenous injection of 2.5 × 105 MKPCs
in week 5 into mice subjected to five-sixths nephrec-
tomy. Quantification of GFP-positive cells was made by
flow cytometry and the result is shown in Additional file
3: Figure S3A. The increase in the number of GFP-
positive cells in the lung peaks at 4 hours, declines at
16 hours, reaches a plateau at 1 day, and is negligible
until 9 weeks after MKPC injection (i.e., the 14th week
after five-sixths nephrectomy). These results were sup-
ported by immunohistochemistry of the lung which
shows GFP-positive cells in the alveoli at the first day
(Additional file 3: Figure S3B). No GFP-positive cells
were found 14 weeks after nephrectomy. These results
suggest that the presence of MKPCs in the lung might
be transient.
These results indicate that the effect of MKPCs on the
preservation of renal function after five-sixths nephrec-
tomy was not mediated through the direct engagement of
the stem cells. We further tested the effect of conditioned
Fig. 2 MKPC injections significantly ameliorate the histologic features of chronic kidney injury in five-sixths nephrectomized mice. a–f Representa-
tive photomicrographs of PAS-stained kidney section before establishment a, and at 14 weeks b, d and 17 weeks c, e of CKD in mice treated with
saline (left) or MKPCs (right). The glomeruloslcerosis was more prominent in the saline group than in the MKPC group 17 weeks after five-sixths
nephrectomy and was expressed by the glomerulosclerosis index f. Scale bar: 50 μm. g–l Representative photomicrographs of Masson’s
trichrome-stained kidney section before establishment g, and at 14 weeks h, j and 17 weeks i, k of CKD in mice treated with saline (left) or MKPCs
(right). Interstitial fibrosis (arrow) was more extensive in the saline group h, i than in the MKPC group j, k. l Fractional interstitial fibrosis area. Scale
bar: 200 μm. m–o Representative photomicrographs of Masson’s trichrome-stained kidney section at 17 weeks of CKD in mice treated with saline
m or MKPCs n. *Five-sixths nephrectomized mice receiving MKPC showed less atrophic tubules, which was expressed by the fractional area of
atrophic tubules o. Scale bar: 100 μm. *P <0.05 MKPC-treated vs. saline-treated group. Data presented as mean ± SD. Masson Masson’s trichrome
stain, MKPC mouse kidney progenitor-like cells, PAS periodic acid-Schiff stain
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medium on renal progression. Five weeks after five-sixths
nephrectomy, mice received treatment with weekly intra-
venous injection of conditioned medium, MKPCs or saline
for 6 weeks. At 17 and 21 weeks, treatment with condi-
tioned medium or MKPCs resulted in similar but signifi-
cantly better renal function compared with treatment with
saline (both P <0.05; Additional file 4: Table S1).
MKPCs reduce the infiltration of inflammatory cells and
promote the proliferation of tubule cells in the five-sixths
nephrectomy model
We evaluated the presence of two major cell types in areas
of renal fibrosis. As shown in Fig. 4, the number of macro-
phages expressing F4/80 in the tubulointerstitium was sig-
nificantly lower in the mice treated with MKPCs than that
in the saline-treated mice. The decreased infiltration of
macrophages in the kidneys treated with MKPCs was
associated with a decreased number of myofibroblasts in
the interstitium. In addition, the mice treated with MKPCs
displayed significantly higher proliferation of tubular cells
14 weeks after the five-sixths nephrectomy than the
saline-treated mice (Fig. 4k, l).
Effects of MKPCs on vascular phenotypes
We examined how MKPCs affected the microvascula-
ture of kidneys after the five-sixths nephrectomy. As
shown in Fig. 5a, b, the capillary rarefaction was signifi-
cantly reduced in the remnant kidney treated with the
MKPCs. EndoMT is considered to be an origin of renal
fibroblasts in CKD. Figure 5d–i show sections of various
regions of kidneys costained for α-SMA and CD31. Sub-
stantial amounts of α-SMA-positive and CD31-positive
cells were observed in the corticomedullary junction of
the kidney treated with saline. By contrast, no α-SMA-
positive and CD31-positive cells were observed in the
MKPC-treated mice. This suggests that MKPCs pre-
vented EndoMT following five-sixths nephrectomy.
Fig. 3 Presence of GFP-positive cells in the kidney of five-sixths nephrectomized mice. a As detected by FACS, the presence of GFP-positive cells
peaked at 2 days and declined at 7 days after injection. After 28 days, few GFP-positive cells were detected in the kidney. Myh9-targeted mutant
mice were used as a positive control and five-sixths nephrectomized mice treated with saline were used as a negative control. Data presented as
mean ± SD. b–e Representative photomicrographs of GFP-stained kidney section 2 days and 14 weeks of CKD in mice treated with MKPCs. Kidney
from Myh9-targeted mutant mouse was used as a positive control b. GFP-positive cells were found in some areas of the interstitium at the
second day c, formed a tubule-like structure in the medulla d (inlet with higher magnification), or remained in the interstitium at 14 weeks.
Scale bar: 50 μm. d days, GFP green fluorescent protein, h hours, M9 Myh9-targeted mutant mice, Saline five-sixths nephrectomized mice
treated with saline
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Fig. 4 MKPC injection decreases the recruitment of inflammatory cells and promotes proliferating tubule cells in five-sixths nephrectomized mice.
a–j Representative photomicrographs illustrate F4/80 and α-SMA expression in the renal tissue of mice receiving saline or MKPC 14 and 17 weeks
after five-sixths nephrectomy. Lower numbers of F4/80-positive cells a–e (arrow) and α-SMA-positive cells f–j (arrow) accumulate in the interstitium of
mice treated with MKPCs compared with those injected with saline. k–m Ki67-positive cells (arrow) are more frequently found in the cortical tubules in
mice receiving MKPC injection 14 weeks after chronic kidney injury. Scale bar: 50 μm. *P <0.05, MKPC-treated vs. saline-treated group. Data presented
as mean ± SD. α-SMA alpha-smooth muscle actin, MKPC mouse kidney progenitor-like cells, Saline five-sixths nephrectomized mice treated with saline,
wk weeks
Fig. 5 MKPC injection preserves capillary density and prevents EndoMT in five-sixths nephrectomized mice. a–c Capillary rarefaction occurs in
five-sixths nephrectomized mice treated with saline a, but MKPC injection preserves capillary density b at 17 weeks after establishment of chronic
kidney injury. Scale bar: 50 μm. d–i Confocal microscopy demonstrates α-SMA (red) and CD31 (green) staining in 17-week nephrectomized mice. Arrows
indicate α-SMA and CD31 double-positive cells in the capillaries. EndoMT occurs in the interstitium of cortex and cortico-medullary junction
from five-sixths nephrectomized mice treated with saline. The MKPC injection prevents EndoMT. Scale bar: 50 μm h, 20 μm i. α-SMA alpha-smooth
muscle actin, Junction cortico-medullary junction of the kidney, MKPC mouse kidney progenitor-like cells, Saline five-sixths nephrectomized mice
treated with saline
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Effects of MKPC-conditioned medium on angiogenic
processes in vitro
To determine whether the conditioned medium of
MKPCs protected against hypoxia-induced cell death in
endothelial cells in vitro, endothelial cells (i.e., MMECs)
were cocultured with the conditioned MKPC medium
following hypoxia for 24 and 28 hours. As shown in Fig. 6a,
the hypoxia dose-dependently enhanced the cell death of
endothelial cells (52.6 ± 1.9 % in hypoxia for 28 hours vs.
38.2 ± 0.9 % in hypoxia for 24 hours vs. 3.5 ± 0.3 % in the
control group; P <0.05; Fig. 6b). Moreover, the condi-
tioned medium from the MKPCs significantly reduced the
amount of hypoxia-induced cell death (P <0.05 vs. without
conditioned medium) after 24 and 28 hours under hyp-
oxic conditions.
TGF-β plays a pivotal role in the development and
progression of renal fibrosis, and EndoMT contributes
to renal fibrosis. To investigate whether the condi-
tioned MKPC medium could prevent TGF-β-induced
EndoMT in vitro, we cultured MMECs in the presence of
TGF-β. Fibroblastoid change of cultured MMECs was ob-
served following TGF-β stimulation, whereas the change
was milder in MMECs incubated with MKPC conditioned
medium (Fig. 6c). Confocal microscopy demonstrated the
TGF-β-induced de novo expression of α-SMA (Fig. 6c), a
putative marker of myofibroblasts. Concurrently, the
MMEC expression of the endothelial cell markers CD31
was lost (Fig. 6d). Confocal microscopy (Fig. 6c) and west-
ern blot (Fig. 6d, e) demonstrated that the conditioned
medium from the MKPCs could significantly reduce the
expression of α-SMA and preserve the expression of
CD31 in endothelial cells treated with TGF-β. Moreover,
western blot analysis shows that MKPC conditioned
medium inhibited TGF-β-induced phosphorylation of
Smad3 in MMECs (Fig. 6f). This indicates that the condi-
tioned MKPC medium could prevent TGF-β-induced
EndoMT through downregulation of phosphorylated
Smad 3 in vitro.
Fig. 6 MKPC conditioned medium promote angiogenic process in vitro. a, b Conditioned medium from MKPCs ameliorates endothelial cell
death following hypoxic culture condition. Endothelial cells (MMECs) were treated with or without conditioned medium from MKPCs (MKPC CM)
under normoxic or hypoxic culture conditions for 24 or 28 hours. Cell death was measured by Annexin V and PI staining detected by flow
cytometry. Each experiment was repeated three times. Cells in the upper left and upper right plots were considered death cells. c–f Conditioned
medium from MKPCs prevents TGF-β-induced EndoMT in vitro. Confocal microscopy demonstrates DAPI (blue), CD31 (green), and α-SMA (red) in
MMECs cultured with or without MKPC CM and with or without TGF-β for 14 days c. Representative western blot and relative bar graph analysis
of CD31, α-SMA d, e, Smad3 and pSmad3 f protein level in MMECs after various treatments. Fibroblast-like change of MMECs was observed
following TGF-β treatment, but the change was reduced in MMECs incubated with MKPC CM c. TGF-β treatment (5 ng/ml) caused increased α-SMA
protein expression and decreased CD31 protein expression d, e. MKPC CM inhibited phosphorylation of Smad3 in MMEC after 1 hour of TGF-β
stimulation f and attenuated these TGF-β-induced EndoMT responses. *P <0.05 compared with control or between two groups. α-SMA alpha-smooth
muscle actin, DAPI 4′,6-diamidino-2-phenylindole, MMEC mouse pancreatic microvascular endothelial cell, TGF-β transforming growth factor beta
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Discussion
Regardless of its etiology, the process of CKD is generally
irreversible and inevitably leads to end-stage renal failure,
a condition requiring life-long dialysis or renal transplant-
ation. In this study, we examined how kidney progenitor-
like cells positively influenced renal outcome after chronic
kidney injury. Although mice died of uremia after experi-
encing chronic renal injuries, treating these mice with
kidney progenitor-like cells saved lives by improving renal
fibrosis. Intravenously injecting MKPCs protected the
mice from renal function deterioration and subsequent
death, by decreasing the EndoMT and preserving angio-
genesis following a five-sixths nephrectomy.
Various studies have indicated that stem cells derived
from the kidney accelerate the recovery of acute kidney
injuries [11–13]. The role of stem cells in the progres-
sion of CKD has primarily been observed in studies that
applied mesenchymal stem cells in various models such
as glomerular basal membrane-associated type IV colla-
gen gene mutations, anti-Thy 1,1-induced glomerulo-
nephritis, unilateral ureteral obstruction, and five-sixths
nephrectomy [7, 8, 14–17]. We selected a five-sixths
nephrectomy model because it is considered to be a
classic model of progressive renal disease characterized
by renal inflammation and the gradual development of
glomerulosclerosis and tubulointerstitial fibrosis, thereby
mimicking CKD in humans [18]. In the study, the MKPC
infusion significantly improved renal function and pro-
longed survival. Anemia and hypertension were also cor-
rected among the MKPC-treated animals, reflecting their
enhanced kidney function. To date, no studies have evalu-
ated the potential benefits of treatment with adult kidney
progenitor-like cells in CKD models. This result is com-
patible with previous studies showing the beneficial effect
of progenitor cells derived from human fetal kidney on
renal function halting disease progression in the five-
sixths nephrectomy model [19, 20].
The mechanism by which the injected MKPCs amelio-
rated renal fibrosis is intriguing and may have resulted from
various factors. After the five-sixths nephrectomy and the
intravenous injection of renal progenitor-like cells, the en-
graftment of MKPCs into tubular or endothelial cells was
observed to be localized in limited areas rather than widely
diffused. Thus, the direct contribution of MKPCs to renal
repair could be minor, as indicated by the results, where
the MKPCs that were detected 2 days after the injection di-
minished over time, representing only 0.08 % of the kidney
cells at 28 days after a single injection.
Alternatively, experimental studies have indicated that
vascular rarefaction in the remnant kidney which occurs
as a result of endothelial damage following chronic kidney
injury is a critical step toward secondary tissue hypoxia
and kidney progression [21–23]. The fibrotic tubulointer-
stitium, which is a hypoxic environment, exacerbates
problems and progressively replaces damaged parenchy-
mal tissue with nonfunctioning scar tissue, leading to
prominent capillary rarefaction [24]. In this study, the
injected MKPCs protected against endothelial injury in
vitro and in vivo. This might facilitate the supply of add-
itional oxygen or regenerative materials to ensure vascular
stability during kidney injury, thereby limiting renal fibro-
sis. A recent study shows that the vasculogenic activity of
endogenous mesenchymal stem cells isolated from mice
of chronic kidney injury was blunted by uremic toxins
[25]. A supply of progenitor-like cells derived from healthy
mice kidney might thus correct the defect and promote
the angiogenic process in mice with chronic kidney
injuries.
Recent evidence has suggested that stem cells down-
regulate the adhesion of flowing neutrophils or lympho-
cytes and their subsequent transendothelial migration
[26]. We observed evidence that the systemic injection
of MKPCs may provide protection by modulating the
recruitment of macrophages. Another study indicated
that the beneficial effects of MKPCs might be mediated
through their ability to supply large amounts of immu-
nomodulatory factors, thereby lessening tissue inflam-
mation in kidney fibrosis [17]. Further studies are
required to uncover the relevant mechanisms. Cell
therapy with renal stem cells may be a strategy for
treating chronic kidney injury. Because of the strong
therapeutic potential of stem cell therapies, the mecha-
nisms and long-term safety of this form of therapy
must be defined.
The accumulation of activated fibroblasts in affected
tissues and the persistence of their elevated biosyn-
thetic functions are crucial determinants of the rate of
progression in renal fibrosis. Studies have suggested
that the activated fibroblasts in fibrotic kidneys origin-
ate from several sources, including the expansion of
resident tissue fibroblasts, migration, and the tissue ac-
cumulation of bone-marrow-derived fibrocytes from
epithelial cells or pericytes that have undergone mesen-
chymal transition [27, 28]. Endothelial cells can also
undergo EndoMT and might be a crucial source of acti-
vated fibroblasts participating in renal fibrosis [29, 30].
Our in vitro experiments demonstrated that the endo-
thelial cells activated by TGF-β expressed α-SMA,
which is a critical marker of EndoMT. Adding condi-
tioned medium from the MKPCs to the culture system
decreased the expression of phosphorylated Smad3 and
α-SMA. The results of a recent study have suggested
that progenitor-like cells secrete antifibrotic agents,
thereby ameliorating kidney and cardiac fibrosis [31].
We speculate that MKPCs can interfere with TGF-β
signaling among endothelial cells, thereby protecting
these cells from damage and delaying the progression
of renal fibrosis.
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Conclusion
In this study, MKPCs ameliorated the progression of fi-
brosis in a remnant kidney model, prolonging the survival
of mice after a five-sixths nephrectomy. We speculate that
the modulation of angiogenic responses may be involved
in this process. This study elucidates the use of cell ther-
apy in treating chronic kidney injury.
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